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Abstract Cerebral microvascular endothelial cells—coming
in contact with pericytes and astrocytes—constitute the struc-
tural basis of the blood-brain barrier (BBB). The continuous
belt of interendothelial tight junctions (TJs) and the presence
of specific transport systems, enzymes, and receptors in the
brain endothelium regulate the molecular and cellular traffic
into the central nervous system. Pituitary adenylate cyclase-
activating polypeptide (PACAP) is a neuropeptide having
several cellular protective effects. However, little is known
about the effects of PACAP on the cerebral endothelium and
BBB functions. Here, we show that PACAP has no significant
pro-survival role in cerebral microvascular endothelial cells;
however, it improves the barrier properties of the brain endo-
thelium. PACAP induces an increase in the transendothelial
electrical resistance, which is the most important marker of the
tightness of the TJs. Moreover, PACAP has a protective
role against glucose deprivation- and oxidative stress-
induced junctional damage in microvascular brain endo-
thelial cells.
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Introduction
Neurons of the vertebrate brain require strictly regulated con-
centrations of ions, neurotransmitters, hormones, and other
biologically active substances. The blood-brain barrier
(BBB) is one of the most important systems responsible for
the maintenance of this microenvironment. The BBB is
formed by brain capillary endothelial cells in close association
with pericytes and astrocytic end feet almost completely cov-
ering the cerebral surface of the endothelium. In comparison
to endothelia of non-cerebral origin, brain endothelia undergo
an additional step of differentiation which results in a specific
cellular phenotype that resembles epithelial cells. In this re-
spect, the most prominent feature of cerebral endothelial cells
is the occurrence of continuous tight junctions (TJs) which
seal the paracellular passage for macromolecules and cells
from the blood stream into the brain parenchyma. Other
characteristics specific to cerebral endothelial cells include
the absence of fenestrations, the paucity of pinocytotic vesi-
cles, the high number of mitochondria, and a variety of trans-
port systems in the luminal and abluminal cellular membrane
(for review see: Abbott et al. 2010; Wilhelm et al. 2011).
Tight junctions regulate the paracellular permeability of the
endothelial layer and also organize the polarization of the
endothelial cell membrane separating an apical and a
basolateral surface. By regulating the traffic of ions, tight
junctions are responsible for establishing the transendothelial
electrical resistance (TEER) between the apical and
basolateral side of the cells. Tight junctions are composed of
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transmembrane proteins, including occludin, claudins (mainly
claudin-5), and junctional adhesion molecules; and cytoplas-
mic plaque proteins which comprise zonula occludens pro-
teins (ZO-1, ZO-2) and associated molecules. Formation and
maintenance of the TJs are supported by the presence of
adherens junctions which are also composed of transmem-
brane and cytoplasmic proteins (the cadherin-catenin and the
nectin-afadin systems). The main cadherin of endothelial cells
is VE-cadherin.
Pituitary adenylate cyclase-activating polypeptide
(PACAP) was originally isolated as a hypophysiotropic neu-
ropeptide (Miyata et al. 1989). Later it was shown that it is
broadly expressed in the central nervous system and in several
other organs as well, including the retina, kidney, immune
cells, reproductive tissues, gastrointestinal tract, etc. PACAP
exerts neuroprotective (Tsuchikawa et al. 2012),
cytoprotective, pro-survival (Brown et al. 2013), anti-
inflammatory, vasodilator, and several other effects (for review
see: Vaudry et al. 2009; Reglodi et al. 2012). PACAP has been
shown to have several effects on microvascular endothelia of
non-cerebral origin: it protects mouse hemangioendothelioma
cells against the apoptosis-inducing effects of oxidative stress
(Racz et al. 2007) and inhibits hyperglycemia-induced prolif-
eration in H5V murine microvascular endothelial cells
(Castorina et al. 2010). However, the effects of PACAP on
brain endothelial cells are incompletely understood. It has been
shown that PACAP exerts an inhibitory effect on prostanoid
synthesis in rat cerebral microvessels via a cyclic adenosine
monophosphate (cAMP)-dependent pathway (Kis et al. 1999).
It has also been shown that PACAP crosses the BBB at a
modest degree. The influx of PACAP into the brain is different
between the two isoforms: PACAP-27 enters the brain by
transmembrane diffusion, while PACAP-38 by a saturable
transport system (Banks et al. 1993). The peptide transport
system-6 (PTS-6) is responsible for the bidirectional transport
of PACAP-38 and for the efflux of PACAP-27 (Dogrukol-Ak
et al. 2009). On the other hand, it has not been investigated
whether PACAP has any effect on the barrier properties of the
brain endothelium.
Material and Methods
Cell Culture and Treatments
The human cerebral microvascular endothelial cell line
(hCMEC/D3, shortly D3) (Weksler et al. 2005) was cultured
on rat tail collagen-coated surfaces in EBM-2 medium (Lonza)
supplemented with 5% FBS (Lonza) and EGM-2 (Lonza). For
immunofluorescence experiments, after reaching confluence,
cells were given 10 mM LiCl for 48 h (Paolinelli et al. 2013).
Primary rat brain microvascular endothelial cells (RBECs)
were isolated from 2–3-week-old Wistar rats, as described
previously (Wilhelm et al. 2007; Hutamekalin et al. 2008).
Briefly, after removal of meninges, cerebral cortices were cut
into small pieces and digested with 1 mg/ml collagenase type
2 for 90 min at 37 °C. After separation of myelin by centrifu-
gation in 20% bovine serum albumin (BSA, Sigma), a second
digestion was performed with 1 mg/ml collagenase/dispase
for 50 min at 37 °C. Microvessel fragments were collected
after centrifugation on Percoll gradient (10 min 1,000 g) and
plated onto fibronectin/collagen-coated dishes. Endothelial
cells growing out of the microvessels were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM)/F12, 10 %
plasma-derived serum (First Link, UK), and growth factors. In
the first 2 days, 4 μg/ml puromycin was added to remove
contaminating cells. After reaching confluence, the endothe-
lial monolayer was gently trypsinized and passed onto filter
inserts (Transwell-Clear, Costar-Corning, 1.12 cm2, 0.4-μm
pore size). The next day, the endothelial monolayer was
supplied with 550 nM hydrocortisone, 250 μM CPT-cAMP,
and 17.5 μM RO-201724.
Rat astrocytes and pericytes were isolated as described
previously (Sziraki et al. 2011) and cultured in DMEM
(LifeTechnologies) supplemented with 10 % FBS (Lonza).
Confluent RBEC or D3 monolayers were treated in serum-
free DMEM or glucose-free DMEM (LifeTechnologies) using
100 nM PACAP1-38 (synthesized at the Department of
Medical Chemistry, University of Szeged). For TEER mea-
surements, cells were treated in complete medium, and
PACAP was applied either in the apical/upper or in the
basolateral/lower or in both chambers. DMNQ (2,3-dimeth-
yl-1,4-naphthoquinone; Sigma) was applied in a concentra-
tion of 25 μM.
RT-PCR
Total RNA was extracted from untreated cells using TRIzol
reagent (LifeTechnologies) following the manufacturer’s rec-
ommendations. RNA was transcribed into complementary
(c)DNA using a reverse transcription kit (Thermo
Scientific). The amplification was performed on a Bio-Rad
iQ5 thermal cycler using Taq polymerase (Roche) under the
following conditions: 40 cycles of 95 °C for 15 s, 56 °C for
30 s, and 72 °C for 30 s. Forward and reverse primers used for
the amplification are listed in Table 1.
Determination of Apoptosis
D3monolayers were treated in serum-free DMEM or glucose-
free DMEM with 25 μM DMNQ and/or 100 nM PACAP for
90 min. Apoptotic cells were stained with anti-cleaved cas-
pase 3 antibody (Cell Signaling). Simultaneously with the
secondary antibody, 0.6 μg/ml Hoechst-33342 was added
for marking the nuclei. The number of apoptotic cells was
compared to the total cell number. We have also analyzed the
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expression profile of apoptosis-related proteins using a human
apoptosis array kit (R&D Systems) according to the manufac-
turer’s instructions.
Measurement of Transendothelial Electrical Resistance
RBECs were grown on semipermeable filters (as described)
and placed into the wells of the cellZscope® instrument
(nanoAnalytics). Cells were treated with PACAP when the
TEER had reached plateau (i.e., the monolayer has reached
total confluence and mature junctions have been formed).
TEER was afterwards monitored for 4 h.
Immunofluorescence
For immunofluorescence studies, cells were cultured on 96-
well plates. Brain endothelial monolayers were fixed using a
mixture of ice cold ethanol/acetic acid (95:5) for 5 min and
then washed three times for 5 min in phosphate-buffered
saline (PBS). After blocking with 3 % BSA for 30 min, the
monolayers were incubated with primary antibodies against
occludin (LifeTechnologies), claudin-5 (LifeTechnologies),
VE-cadherin (Santa Cruz), or ZO-1 (LifeTechnologies).
After washing, Cy3- or Alexa488-conjugated secondary anti-
bodies (Jackson ImmunoResearch) were applied, followed by
a second washing step. Distribution of the signal was studied
using a Nikon Eclipse TE2000U photomicroscope with
epifluorescent capabilities connected to a digital camera
(Spot RT KE, Diagnostic Instruments).
Western-Blot Analysis
Cells were washed with PBS and scraped into ice-cold
radioimmunoprecipitation assay (RIPA) lysis buffer (20 mM
Tris (pH=7.4), 150 mM NaCl, 1 % sodium deoxycholate,
0.1 % sodium dodecyl sulfate, 1 mM sodium vanadate,
10 mM NaF, 1 mM Pefabloc) and incubated on ice for
30 min. Lysates were clarified by centrifugation at 10,000 g
for 10 min on 4 °C. The protein concentration of the super-
natants was determined with the bicinchoninic acid (BCA)
method (Pierce). Samples were mixed with Laemmli buffer
(final concentration: 12 mM Tris-HCl (pH=6.8), 5 % glycer-
ol , 0 .4 % sodium dodecyl sul fa te , 14.4 μM 2-
mercaptoethanol, 0.02 % bromophenol blue) and boiled for
3 min. Proteins were electrophoresed with standard denaturing
SDS-PAGE procedures and blotted on nitrocellulose mem-
branes (Protran or Bio-Rad). Blocking the non-specific bind-
ing capacity of the membranes was carried out at room tem-
perature for 30 min in TBS-T (Tris buffered saline with 0.1 %
Tween 20) containing 3 % BSA or 5 % casein (non-fat milk
powder). Blots were then incubated with the primary
antibodies. After washing the membranes three times
for 10 min in TBS-T, blots were incubated with the
secondary antibodies (Pierce), then washed again three
times for 10 min in TBS-T. The immunoreaction was
visualized using Immobilon Western Chemiluminescent
HRP Substrate (Millipore) on X-ray film (Agfa).
Densitometric analysis was performed using the ImageJ
software.
Results
Characterization of the Expression of PACAP and PACAP
Receptors on Cells Forming the BBB
First we studied the expression of PACAP and its receptors on
brain endothelial cells (primary rat brain microvascular endo-
thelial cells and the human microvascular cerebral endothelial
cell line D3) using reverse transcription polymerase chain
reaction (RT-PCR). In order to avoid false positive results
originating from genomic contamination, all primer pairs were
designed from different exons (Table 1). As shown on Fig. 1,
we found the presence of PACAP and VPAC2 messenger
(m)RNA in both types of brain endothelial cells analyzed
and VPAC1 in the human endothelial cell line. PAC1 receptor
was expressed neither in rat nor in human brain endothelial
cells. We have also analyzed the expression of PACAP and
PACAP receptors on other cells associated with the BBB.
Astrocytes expressed PACAP and all the three receptors,
while in pericytes we could detect the mRNA of VPAC2
and low amounts of PAC1 and VPAC1.
Table 1 Primers used
Sequence (5′-3′) Reference
Rat primers
rPACAP fw ATGTCGCCCACGAAATCCTT
rPACAP rv TGTCTGTGAAGATGCCGTCC
rPAC1 fw AAATGCTACTGCAAGCCACA
rPAC1 rv GCTCTTGCTCAGGATGGACA
rVPAC1 fw GTGAAGACCGGCTACACCAT Giunta et al. 2012
rVPAC1 rv TGAAGAGGGCCATATCCTTG
rVPAC2 fw AGAGCCATCTCTGTGCTGGT
rVPAC2 rv AGGTAGGCCAGGAAACACCT
Human primers
hPACAP fw CGGGAGGAGTTGAAGGAATGA
hPACAP rv GACAGCCATTTGTTTCCGGT
hPAC1 fw AGCATCTACTTCAGCTGCGTG
hPAC1 rv TTCCAGCTTCGCCATTTTCG
hVPAC1 fw ATGTGCAGATGATCGAGGTG Basille et al. 2006
hVPAC1 rv TGTAGCCGGTCTTCACAGAA
hVPAC2 fw CTTCAGGAAGCTGCACTGC
hVPAC2 rv CAAACACCATGTAGTGGACG
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Effect of PACAP on the Survival of Brain Endothelial Cells
Since PACAP was shown to attenuate apoptosis in
mouse hemangioendothelioma (Racz et al. 2007) and
several other cell types (Seaborn et al. 2011), we
wanted to test whether PACAP also had anti-apoptotic
effect in brain endothelial cells. We examined cells
exposed to glucose deprivation and/or oxidative stress
(using DMNQ) treated or not with 100 nM PACAP1-38.
Apoptosis was detected using immunostaining of
cleaved caspase 3 positive cells (Fig. 2a) and an anti-
body array (Fig. 2b and Suppl. Fig. 1B). Although clear
morphological changes and cell death were detected
(Suppl. Fig. 1A), we have observed only a slight induc-
tion of the number of apoptotic cells and apoptotic
markers in response to glucose deprivation and oxida-
tive stress. Our results showed that PACAP had no
significant anti-apoptotic or pro-survival effect in cere-
bral endothelial cells (Fig. 2 and Suppl. Fig. 1).
Effect of PACAP on the Junctional Complex of Brain
Endothelial Cells
Our main goal, however, was to understand whether PACAP
influenced the tight and adherens junctions of cerebral endo-
thelial cells. Therefore, we measured the transendothelial
electrical resistance (TEER), which is a very sensitive marker
of the paracellular barrier. PACAP1-38 induced a marked
increase in TEER when applied in the apical (upper) compart-
ment, but no effect was observed when applied in the
basolateral (lower) compartment (Fig. 3). The effect appeared
immediately after administration: PACAP attenuated the me-
dium change-induced TEER drop and maintained the TEER
at higher levels in comparison to the control. When applied to
both the apical and the basolateral side or when lower PACAP
concentrations were administered (not shown), the effect was
slighter and lasted for a shorter time.
As a next step, we examined whether PACAP had a pro-
tective effect on the disassembly of the junctions induced by
Fig. 1 Expression of PACAP and
PACAP receptors on cells of the
BBB. RT-PCR was performed
using cDNA isolated from
primary RBECs, rat astrocytes
and pericytes, and the human
cerebral endothelial cell line D3.
One representative of three
independent experiments (in case
of primary cells: of three
independent cell isolations) is
shown. Positive controls: rat brain
and human tonsil, negative
controls: non-template reactions
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different pathological conditions. Glucose deprivation and
DMNQ-induced oxidative stress alone or in combination in-
duced the disruption of the continuous membrane staining of
the junctional proteins ZO-1, VE-cadherin, occludin, and
claudin-5 (Fig. 4 and Suppl. Fig. 2). In the presence of glucose
deprivation or DMNQ-induced oxidative stress, we observed
several holes on the membrane staining. When glucose dep-
rivation and oxidative stress were applied concomitantly, we
observed an almost total disappearance of the transmembrane
junctional proteins from the cell membranes. Arrows in Fig. 4
and Suppl. Fig. 2 point to the discontinuities in the membrane
staining. Transmembrane proteins (VE-cadherin, occludin,
and claudin-5) were more sensitive to stress-induced disrup-
tion than the cytoplasmic protein ZO-1.
PACAP treatment alone induced a stronger junctional
staining of claudin-5, occludin (Suppl. Fig. 2), ZO-1, and
VE-cadherin (Fig. 4) in RBECs. The same effect was seen
in D3 cells which do not form such a tight barrier as
primary cells (Fig. 4). Moreover, PACAP had a protective
effect on glucose deprivation- and/or DMNQ-induced
junctional disassembly in both RBECs and D3 cells, i.e.,
no or less holes could be observed on the membrane
stainings and the territories with absent membrane staining
were much smaller. PACAP treatment could almost totally
maintain the continuity of the tight and adherens junctions
in glucose-free conditions in both brain endothelial cell
types analyzed and could significantly improve the
DMNQ-induced junctional disassembly. When glucose
deprivation and oxidative stress were applied concomitant-
ly, we observed an almost total disappearance of the
ref. ref.
Bad Bax Bcl-2 Bcl-x pro-casp3 cl. casp3 catalase cIAP-1 cIAP-25 claspin clusterin cyt. C
Trail-1 Trail-2 Fadd Fas HIF-1a HO-1 HO-2 Hsp27 Hsp60 Hsp70 HtrA2 livin
PON2 p21 p27 P-p53 P-p53 P-p53 P-Rad17 Smac survivin TNF-R1 TSIAP neg.
ref.
Fig. 2 Evaluation of apoptosis in
brain endothelial cells. D3 cells
were exposed to glucose
deprivation- and/or DMNQ-
induced oxidative stress in the
absence or presence of 100 nM
PACAP. a Cleaved caspase 3
positive cells were counted and
compared to the total number of
nuclei. bCell lysates were applied
onto the human apoptosis array
kit. Quantitative analysis of the
data is shown on Suppl. Fig. 1B
Fig. 3 Effect of PACAP on the TEER of cerebral endothelial cells.
RBECs were cultured on semipermeable filter inserts. PACAP was ap-
plied in a concentration of 100 nM either in the upper, lower, or both (u+l)
compartments. TEER was monitored using the cellZscope® system.
Values are % control at start of the experiment, representing average±
SD. *p<0.05 as assessed by ANOVA and Bonferroni’s post hoc test (red
indicates PACAP upper vs. control, violet indicates PACAP u+l vs.
control). One representative of three independent experiments is presented
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transmembrane junctional proteins from the cell mem-
branes and a severe disruption of the ZO-1 staining.
PACAP could partly reverse these effects (Fig. 4).
To test whether PACAP influenced not only the localiza-
tion but also the expression of the junctional proteins, we
performed Western-blot experiments. Our results indicated
that PACAP did not significantly induce the expression of
tight and adherens junction proteins in RBECs or D3 cells
(Fig. 5 and Suppl. Fig. 3). Only the amount of occludin
increased in D3 cells, but not in the tight barrier forming
RBECs. We observed a decrease in the amount of ZO-1
protein in response to glucose-free conditions combined with
DMNQ; however, this was not affected by PACAP.
Discussion
Pituitary adenylate cyclase-activating polypeptide and its re-
ceptors have been shown to have widespread distributions in
organism. However, the expression of PACAP and PACAP
receptors on cells of the BBB has not been investigated so far,
except for astrocytes, which have been shown to express
PACAP, PAC1, VPAC1, and VPAC2 (Grimaldi and
Cavallaro 1999; Jaworski 2000). In accordance with literature
data, we showed the presence of PACAP and its three
receptors on astrocytes. Additionally, we observed the
presence of VPAC2 and low amounts of PAC1 and
VPAC1 in brain pericytes. We also showed that
Fig. 4 a–d Effect of PACAP on
the localization of tight and
adherens junction proteins.
RBECs or D3 cells were exposed
to glucose deprivation- and/or
DMNQ-induced oxidative stress
in the absence or presence of
100 nM PACAP.
Immunofluorescence stainings
were performed using anti-ZO-1
or anti-VE-cadherin antibodies.
Junctional disruption (indicated
by arrows) is represented by the
discontinuity or disappearance of
the membrane staining. One
representative of three
independent experiments is
presented
474 J Mol Neurosci (2014) 54:469–476
microvascular cerebral endothelial cells expressed
PACAP. In accordance, isolated brain microvessels have
been shown to release PACAP, which is decreasing with
age (Tripathy et al. 2012).
We also detected VPAC2 in cerebral endothelial cells,
while VPAC1 was present only in human, but not in rat brain
endothelial cells. We have observed that PACAP treatment
induced amarked increase in TEERwhen applied in the apical
(upper) compartment. This suggests that PACAP receptors are
probably present in the apical and not in the basolateral
membrane. The two membrane parts are divided by the tight
junctions which prevent the diffusion of proteins and lipids
between the apical and the basolateral membranes.
Interestingly, in the rat middle cerebral artery, all three
PACAP receptors were found to be present and abluminal
but not luminal VIP, PACAP-27, and PACAP-38 caused
concentration-dependent arterial relaxations (Erdling et al.
2013), underlying the difference between macrovascular and
BBB-forming microvascular brain endothelial cells.
According to our results, PAC1 was present neither in
human nor in rat brain microvascular endothelial cells. Since
most of the anti-apoptotic effects of PACAP are mediated
through the PAC1 receptor (Seaborn et al. 2011), the absence
of PAC1 from our cells may explain the lack of a significant
pro-survival effect of PACAP on cerebral microvascular en-
dothelial cells. Interestingly, although in response to glucose
deprivation and oxidative stress marked cell death was ob-
served (Suppl. Fig. 1A), this was not accompanied by the
induction of apoptotic markers. This suggests that another
type of cell death occurred (e.g., necrosis); however, we did
not investigate in details the molecular processes leading to
cell death. Nevertheless, glucose deprivation- and/or oxidative
stress-induced brain endothelial cell death was not reversed by
the presence of PACAP.
The interaction of PACAP with the cerebral endothelium is
far from being well-understood and mainly restricted to
macrovessels. PACAP-27 and PACAP-38 were shown to be
potent vasodilators in porcine neonatal pial vessels and rat
middle cerebral artery (Lenti et al. 2007; Erdling et al. 2013).
On the other hand, the effects of PACAP on microvascular
brain endothelial cells, which form the BBB, are not well-
characterized. High concentrations of PACAP (10 nM–1 μM)
were shown to significantly inhibit the activity of the cycloox-
ygenase pathway in isolated cerebral microvessels (Kis et al.
1999). However, the effects of PACAP on the barrier properties
of the brain endothelium have not been investigated so far.
Capillary endothelial cells of the brain parenchyma form a
restrictive paracellular barrier by the presence of well-
developed tight junctions. cAMP is known to increase the
transendothelial electrical resistance (TEER), which is the
most important marker of the tightness of the TJs (for review
see: Krizbai and Deli 2003). Intracellular cAMP is known to
strengthen the barrier function of the cerebral endothelium
(Stelzner et al. 1989; Rubin et al. 1991; Rubin and Staddon
1999; Ishizaki et al. 2003). Moreover, cAMP-elevating
agents, like adrenomedullin or cilostazol have also been
shown to stabilize the tight junctions of cerebral endothelial
cells (Kis et al. 2001; Horai et al. 2013). Nevertheless, all three
receptors of PACAP (PAC1, VPAC1, and VPAC2) signal
mainly through the cAMP/PKA pathway. Hence, we have
focused our investigations on the potential effects of PACAP
on the TJs of cerebral endothelial cells.
Our results show that PACAP stabilizes the junctional
proteins in the membrane of brain endothelial cells in both
control and pathological conditions. cAMP has been shown to
induce the expression and phosphorylation of claudin-5
Fig. 5 Effect of PACAP on the expression of tight and adherens junction
proteins. RBECs or D3 cells were exposed to glucose deprivation- and
DMNQ-induced oxidative stress in the absence or presence of 100 nM
PACAP. Western-blot experiments were performed using the RIPA-solu-
ble fractions.β-Actin was used as a loading control. One representative of
three independent experiments is presented. Quantitative analysis is
shown on Suppl. Fig. 3
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through different mechanisms and to enhance signals of
claudin-5, occludin, ZO-1, ZO-2, and VE-cadherin along cell
boundaries (Ishizaki et al. 2003). PACAP had no effect on the
expression of the junctional proteins; however, the membrane
staining of several tight and adherens junction proteins in-
creased significantly, suggesting that PACAP induces junc-
tional proteins to localize to the intercellular contacts.
In summary, this is the first report that PACAP improves
the function of the tight junctions of cerebral endothelial cells
without affecting their survival.
Acknowledgments This work was supported by grants from the
Hungarian Research Fund (OTKA PD-100958, K-100807, K-104984),
the National Development Agency (Hungary-Romania Cross-Border Co-
operation Program 2007-2013: HURO/1101/173/2.2.1, the TÁMOP-
4.2.2.A-11/1/KONV-2012-0024, and 4.2.2.A-11/1/KONV-2012-0052
projects), the PTE-MTA “Lendület” Program, NAP, and the Arimura
Foundation. I. Wilhelm was supported by the János Bolyai Research
Fellowship of the Hungarian Academy of Sciences (BO/00320/12/8).
The research of C. Fazakas and A. Tamás was supported by the
European Union and the State of Hungary, co-financed by the European
Social Fund in the framework of TÁMOP-4.2.4.A/2-11/1-2012-0001
“National Excellence Program.”
References
Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010)
Structure and function of the blood-brain barrier. Neurobiol Dis 37:
13–25
BanksWA, Kastin AJ, Komaki G, Arimura A (1993) Passage of pituitary
adenylate cyclase activating polypeptide1-27 and pituitary adenylate
cyclase activating polypeptide1-38 across the blood-brain barrier. J
Pharmacol Exp Ther 267:690–696
Basille M, Cartier D, Vaudry D et al (2006) Localization and character-
ization of pituitary adenylate cyclase-activating polypeptide recep-
tors in the human cerebellum during development. J Comp Neurol
496:468–478
Brown D, Tamas A, Reglodi D, Tizabi Y (2013) PACAP protects against
salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: impli-
cation for Parkinson’s disease. J Mol Neurosci 50:600–607
Castorina A, Giunta S, Mazzone V, Cardile V, D’Agata V (2010) Effects
of PACAP and VIP on hyperglycemia-induced proliferation in
murine microvascular endothelial cells. Peptides 31:2276–2283
Dogrukol-Ak D, Kumar VB, Ryerse JS et al (2009) Isolation of peptide
transport system-6 from brain endothelial cells: therapeutic effects
with antisense inhibition in Alzheimer and stroke models. J Cereb
Blood Flow Metab 29:411–422
Erdling A, Sheykhzade M, Maddahi A, Bari F, Edvinsson L (2013) VIP/
PACAP receptors in cerebral arteries of rat: characterization, localiza-
tion and relation to intracellular calcium. Neuropeptides 47:85–92
Giunta S, Castorina A, Bucolo C, Magro G, Drago F, D’Agata V (2012)
Early changes in pituitary adenylate cyclase-activating peptide, va-
soactive intestinal peptide and related receptors expression in retina
of streptozotocin-induced diabetic rats. Peptides 37:32–39
Grimaldi M, Cavallaro S (1999) Functional and molecular diversity of
PACAP/VIP receptors in cortical neurons and type I astrocytes. Eur
J Neurosci 11:2767–2772
Horai S, Nakagawa S, Tanaka K et al (2013) Cilostazol strengthens barrier
integrity in brain endothelial cells. Cell Mol Neurobiol 33:291–307
Hutamekalin P, Farkas AE, Orbok A et al (2008) Effect of nicotine and
polyaromtic hydrocarbons on cerebral endothelial cells. Cell Biol Int
32:198–209
Ishizaki T, Chiba H, Kojima T et al (2003) Cyclic AMP induces phosphor-
ylation of claudin-5 immunoprecipitates and expression of claudin-5
gene in blood-brain-barrier endothelial cells via protein kinase A-
dependent and -independent pathways. Exp Cell Res 290:275–288
Jaworski DM (2000) Expression of pituitary adenylate cyclase-activating
polypeptide (PACAP) and the PACAP-selective receptor in cultured
rat astrocytes, human brain tumors, and in response to acute intra-
cranial injury. Cell Tissue Res 300:219–230
Kis B, Gaspar T, Mezei Z, Gecse A, Telegdy G (1999) Pituitary adenylate
cyclase-activating polypeptide inhibits the cyclooxygenase pathway
of rat cerebral microvessels. Acta Physiol Scand 167:43–47
Kis B, Deli MA, Kobayashi H et al (2001) Adrenomedullin regulates
blood-brain barrier functions in vitro. Neuroreport 12:4139–4142
Krizbai IA, Deli MA (2003) Signalling pathways regulating the tight
junction permeability in the blood-brain barrier. Cell Mol Biol
(Noisy-Le-Grand) 49:23–31
Lenti L, Domoki F, Kis D et al (2007) Pituitary adenylate cyclase-
activating polypeptide induces pial arteriolar vasodilation through
cyclooxygenase-dependent and independent mechanisms in new-
born pigs. Brain Res 1165:81–88
Miyata A, Arimura A, Dahl RR et al (1989) Isolation of a novel 38 residue-
hypothalamic polypeptide which stimulates adenylate cyclase in pitu-
itary cells. Biochem Biophys Res Commun 164:567–574
Paolinelli R, Corada M, Ferrarini L et al (2013) Wnt activation of immor-
talized brain endothelial cells as a tool for generating a standardized
model of the blood brain barrier in vitro. PLoS One 8:e70233
Racz B, Gasz B, Borsiczky B et al (2007) Protective effects of pituitary
adenylate cyclase activating polypeptide in endothelial cells against
oxidative stress-induced apoptosis. Gen Comp Endocrinol 153:115–
123
Reglodi D, Kiss P, Szabadfi K et al (2012) PACAP is an endogenous
protective factor-insights from PACAP-deficient mice. J Mol
Neurosci 48:482–492
Rubin LL, Staddon JM (1999) The cell biology of the blood-brain barrier.
Annu Rev Neurosci 22:11–28
Rubin LL, Hall DE, Porter S et al (1991) A cell culture model of the
blood-brain barrier. J Cell Biol 115:1725–1735
Seaborn T, Masmoudi-Kouli O, Fournier A, Vaudry H, Vaudry D (2011)
Protective effects of pituitary adenylate cyclase-activating polypep-
tide (PACAP) against apoptosis. Curr Pharm Des 17:204–214
Stelzner TJ, Weil JV, O’Brien RF (1989) Role of cyclic adenosine
monophosphate in the induction of endothelial barrier properties. J
Cell Physiol 139:157–166
Sziraki I, Erdo F, Beery E et al (2011) Quinidine as an ABCB1 probe for
testing drug interactions at the blood-brain barrier: an in vitro in vivo
correlation study. J Biomol Screen 16:886–894
Tripathy D, Sanchez A, Yin X, Martinez J, Grammas P (2012) Age-
related decrease in cerebrovascular-derived neuroprotective pro-
teins: effect of acetaminophen. Microvasc Res 84:278–285
Tsuchikawa D, Nakamachi T, Tsuchida M et al (2012) Neuroprotective
effect of endogenous pituitary adenylate cyclase-activating polypep-
tide on spinal cord injury. J Mol Neurosci 48:508–517
Vaudry D, Falluel-Morel A, Bourgault S et al (2009) Pituitary adenylate
cyclase-activating polypeptide and its receptors: 20 years after the
discovery. Pharmacol Rev 61:283–357
Weksler BB, Subileau EA, Perriere N et al (2005) Blood-brain barrier-
specific properties of a human adult brain endothelial cell line.
FASEB J 19:1872–1874
Wilhelm I, Farkas AE, Nagyoszi P et al (2007) Regulation of cerebral
endothelial cell morphology by extracellular calcium. Phys Med
Biol 52:6261–6274
Wilhelm I, Fazakas C, Krizbai IA (2011) In vitro models of the blood-
brain barrier. Acta Neurobiol Exp (Wars) 71:113–128
476 J Mol Neurosci (2014) 54:469–476
